Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

2670
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

SANOFI : S NEW BASAL INSULIN LANTUS XR, KNOWN AS TOUJEO IN THE U.S. AND EUROPE, APPROVED IN JAPAN FOR THE TREATMENT OF DIABETES MELLITUS

07/03/2015 | 06:03am US/Eastern

Release date- 03072015 - Paris, France - Sanofi announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing authorization for insulin glargine [rDNA origin] injection, 300 U/mL, a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus, where treatment with insulin is needed.

Known as Toujeo in the U.S. and Europe, the new insulin treatment will be available in Japan under the trade name Lantus XR.

'For patients requiring basal insulin, Lantus XR could positively impact hypoglycemia during the critical initiation phase, when most titration occurs, and beyond,' said Professor Masato Odawara of Tokyo Medical University. 'Japan-specific data show that Lantus XR patients experienced less nocturnal hypoglycemia and no increase in hypoglycemia at any time of the day. This outcome was delivered with glycemic control comparable to Lantus and is consistent with the findings in the global EDITION program in people with type 2 diabetes.'

According to the MHLW, there are approximately 9.5 million people living with diabetes in Japan.1

'In just four months, Sanofi's next generation basal insulin has been granted marketing authorization by three major regulatory authorities,' said Pierre Chancel, Senior Vice President, Head of Global Diabetes, Sanofi. 'This first approval in Asia adds to the momentum of an active launch year, and it highlights our commitment to improving diabetes care worldwide.'

The MHLW decision is based on the results of the EDITION Phase III study program,2-7 an extensive series of studies evaluating the efficacy and safety of Toujeo / Lantus XR compared with Lantus in more than 3,500 adults with type 1 or type 2 diabetes who were uncontrolled on their current therapy. The EDITION program established the favorable Toujeo / Lantus XR efficacy and safety profile and included the EDITION JP 1 and JP 2 studies,6, 7 which involved over 450 Japanese people with type 1 or type 2 diabetes.

Toujeo is now available in the U.S., Germany, Denmark and the Netherlands and has been registered in Australia. The product will become available in other countries in the coming months.

About Toujeo / Lantus XR

Despite basal insulin being a cornerstone treatment for diabetes for decades, significant unmet medical needs remain a reality, with approximately half of patients on treatment not reaching their blood sugar level targets.8-13 In addition, optimal insulin dose is often not reached during initiation or maintenance phase. Toujeo / Lantus XR is a next-generation, once-daily basal insulin based on a broadly-used molecule (insulin glargine) with a well-established benefit-risk profile.14 Its compact subcutaneous depot leads to more stable and more prolonged pharmacokinetic/pharmacodynamic (PK/PD) profiles.15-17 The approved brand name for insulin glargine (rDNA origin) injection 300 U/mL in countries other than Japan is Toujeo; its brand name in Japan is Lantus XR. Toujeo has been approved by the U.S. Food and Drug Administration (FDA), the European Commission and Health Canada, and is under review by other regulatory authorities around the world.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

References

1. Ministry of Health Labour and Welfare. National Health Nutrition Survey 2012. Available from: http://www.mhlw.go.jp/file/04-Houdouhappyou-10904750-Kenkoukyoku-Gantaisakukenkouzoushinka/0000032813.pdf

2. Riddle MC, Bolli GB, Ziemen M, et al. Diabetes Care. 2014;37(10):2755-62, DOI: 10.2337/dc14-0991

3. Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. Diabetes Care. 2014;37(12):3235-43, DOI: 10.2337/dc14-0990

4. Bolli GB, Riddle MC, Bergenstal RM, et al. Diabetes Obes Metab. 2015;17(4):386-94, DOI: 10.1111/dom.12438

5. Home PD, Bergenstal RM, Bolli GB, et al. Diabetes Care. 2015;Online ahead of print, DOI: 10.2337/dc15-0249

6. Matsuhisa M, Koyama M, Cheng X, et al. EASD; September 15-19; Vienna2014. ePoster abstract #975

7. Terauchi Y, Koyama M, Cheng X, et al. EASD; September 15-19; Vienna2014. ePoster abstract #976

8. Banegas JR, Lopez-Garcia E, Dallongeville J, et al. Eur Heart J. 2011;32(17):2143-52, DOI: 10.1093/eurheartj/ehr080

9. Chan JCN, Gagliardino JJ, Baik SH, et al. Diabetes Care. 2009;32(2):227-33, DOI: 10.2337/dc08-0435

10. Choi YJ, Kim HC, Kim HM, et al. Diabetes Care. 2009;32(11):2016-20, DOI: 10.2337/dc08-2228

11. Stark Casagrande S, Fradkin JE, Saydah SH, et al. Diabetes Care. 2013;36(8):2271-9, DOI: 10.2337/dc12-2258

12. Steinberg BA, Bhatt DL, Mehta S, et al. American Heart Journal. 2008;156(4):719-27, DOI: 10.1016/j.ahj.2008.05.020

13. Vouri SM, Shaw RF, Waterbury NV, et al. J Manag Care Pharm. 2011;17(4):304-12

14. Gerstein HC, Bosch J, Dagenais GR, et al. N Engl J Med. 2012;367(4):319-28, DOI: 10.1056/NEJMoa1203858

15. Shiramoto M, Eto T, Irie S, et al. Diabetes Obes Metab. 2015;17(3):254-60, DOI: 10.1111/dom.12415

16. Becker RHA, Dahmen R, Bergmann K, et al. Diabetes Care. 2015;38(4):637-43, DOI: 10.2337/dc14-0006

17. Steinstraesser A, Schmidt R, Bergmann K, et al. Diabetes Obes Metab. 2014;16(9):873-6, DOI: 10.1111/dom.12283

(c) 2015 Electronic News Publishing -, source ENP Newswire

React to this article
Latest news on SANOFI
07/03 SANOFI : S new basal insulin lantus xr, known as toujeo in the u.s. and europe, ..
07/03 ZHEJIANG HISUN PHARMACEUTICAL : Pharma Enters into Memorandum of Understanding (..
07/03DJSANOFI : Gets Approval from Japan for Toujeo Diabetes Drug
07/03 SANOFI : New Basal Insulin Lantus® XR, Known as Toujeo® in the U.S. and Europe, ..
07/02 Ergomed Appoints Andrew Mackie As Executive Director
07/02DJErgomed Appoints Andrew Mackie as Chief Business Officer
07/02 SANOFI : Signs a Global Agreement with SUEZ environnement To Enhance Water and W..
07/01 Harvard Apparatus Regenerative Technology Appoints James McGorry as New Chief..
07/01DJNovo Nordisk to Stop Selling Key Insulin Drug in Germany
07/01DJSarepta Hires ex-Genzyme Head Henri Termeer as Adviser
Advertisement
Chart
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials